Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Fresh Options Are Emerging for Relapsed DLBCL

April 7th 2020

Although considerable progress has been made in treating diffuse large B-cell lymphoma since the advent of chemoimmunotherapy, approximately 33% of patients still develop relapsed/refractory disease, which is associated with considerable morbidity and mortality.

Dr. Barr on Umbralisib/Ublituximab/Venetoclax in Relapsed/Refractory CLL

April 7th 2020

Paul M. Barr, MD, Wilmot Cancer Institute, University of Rochester, discusses the results of a phase I/II study evaluating the combination of umbralisib, ublituximab, and venetoclax (Venclexta) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

Dr. Goodman on the Importance of the ECHELON-2 Data in PTCL

April 4th 2020

Aaron Goodman, MD, hematologist/oncologist and assistant professor of medicine at the University of California, San Diego, discusses the importance of the phase III ECHELON-2 data in peripheral T-cell lymphoma (PTCL).

FDA Approves Luspatercept for MDS-Associated Anemia

April 4th 2020

The FDA has approved luspatercept for the treatment of anemia in patients with myelodysplastic syndromes.

MRD Assessment Gains Momentum in Hematologic Malignancies

April 3rd 2020

Jerald P. Radich, MD, discusses the growing importance of MRD assessment in the treatment paradigm for patients with hematologic malignancies.

Rituximab Biosimilar Ruxience Approved in Europe

April 2nd 2020

The European Commission has approved the rituximab biosimilar Ruxience for the treatment of patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris

FDA Grants Remestemcel-L Priority Review for Pediatric GVHD

April 1st 2020

The FDA has granted remestemcel-L a priority review designation for the treatment of children with steroid-refractory acute graft versus host disease.

Dr. Altomare on Treatment Options in ITP

April 1st 2020

Ivy P. Altomare, MD, discusses treatment options for patients with immune thrombocytopenia purpura.

Dr. Foss on the Unmet Need in Cutaneous T-cell Lymphoma

March 31st 2020

Francine Foss, MD, discusses the challenges faced in cutaneous T-cell lymphoma.

Brentuximab Vedotin Approaches European Approval for Frontline ALCL

March 31st 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of brentuximab vedotin (Adcetris) for use in combination with chemotherapy for the frontline treatment of adult patients with systemic anaplastic large cell lymphoma.

First CRISPR Cancer Results Fuel Hope

March 30th 2020

Results from the first FDA-approved in-human trial of CRISPR-edited T cells for cancer treatment suggest that such therapies can be used safely in patients, allaying some of the concerns about potential AEs and advancing progress toward the development of more effective cell-based immunotherapies.

Dr. Schmaier on Managing Thrombosis in Hematologic Malignancies

March 28th 2020

Alvin H. Schmaier, MD, discusses managing thrombosis in patients with hematologic malignancies.

Dr. Radich on the Utility of MRD in Hematologic Malignancies

March 28th 2020

Jerald P. Radich, MD, discusses the utility of minimal residual disease in hematologic malignancies.

Dr. Lonial on the Role of Targeted Therapy in AML and ALL

March 28th 2020

Sagar Lonial, MD, FACP, discusses the role of targeted therapy in acute myeloid leukemia and acute lymphoblastic leukemia.

Luspatercept Data Published in NEJM Highlight Benefit for Beta Thalassemia-Associated Anemia

March 28th 2020

Results from the pivotal phase III BELIEVE trial, which supported the FDA approval of luspatercept-aamt for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions, have been published in the New England Journal of Medicine.

Hematopoietic Stem Cell Transplant: A Viable Option for Older Patients With AML

March 28th 2020

The challenge in caring for older patients is developing a risk-adapted strategy that best meets the patients’ identified goals and accounts for a realistic assessment of hematopoietic stem cell transplantation suitability.

Isatuximab Nears European Approval for Relapsed/Refractory Myeloma

March 27th 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended isatuximab in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma who have received ≥2 prior therapies.

Dr. Burke on the Ongoing First-MIND Trial With Tafasitamab in DLBCL

March 27th 2020

John M. Burke, MD, associate chair of the Hematology Research Program for US Oncology and medical oncologist and hematologist at Rocky Mountain Cancer Centers, discusses the ongoing phase Ib First-MIND trial in diffuse large B-cell lymphoma (DLBCL).

Dr. Viprakasit on the Results of the BELIEVE Trial With Luspatercept in Beta-Thalassemia

March 27th 2020

Vip Viprakasit, MD, DPhil, professor of Pediatrics, and director, Thalassemia Research, Siriraj-Thalassemia Center, Siriaj Hospital, discusses the results of the multicenter BELIEVE trial with luspatercept (Reblozyl) in adult patients with β-thalassemia.

Dr. Schuster on GO29781 Trial With Mosunetuzumab in NHL

March 27th 2020

Stephen J. Schuster, MD, director of the Lymphoma Program, director of Translational Research, Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clincai Care and Research at University of Pennsylvania, discusses the results of the phase I/Ib dose-escalation GO29781 trial (NCT02500407) with mosunetuzumab in relapsed/refractory non-Hodgkin lymphoma (NHL).